Literature DB >> 14529551

Bioactivity and pharmacological actions of carbon monoxide-releasing molecules.

Roberto Motterlini1, Brian E Mann, Tony R Johnson, James E Clark, Roberta Foresti, Colin J Green.   

Abstract

Carbon monoxide (CO) is a resourceful gas as recent advances in the area of cell signaling are revealing an unexpected physiological role for CO in the cardiovascular, immune and nervous systems. Transition metal carbonyls have been lately discovered to function as CO-releasing molecules (CO-RMs) and elicit distinct pharmacological activities in biological systems. Studies currently ongoing in our laboratories are investigating both the chemical and bioactive features of a series of water-soluble CO-RMs and their specific utilization as vasoactive mediators, anti-inflammatory agents and inhibitors of cellular and tissue damage. The data presented in this review corroborate the notion that transition metal carbonyls could be used as carriers to deliver CO in mammals and highlight the bioactivity and potential therapeutic features of CO-RMs in the mitigation of cellular and organ dysfunction.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14529551     DOI: 10.2174/1381612033453785

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  60 in total

1.  Exogenous carbon monoxide suppresses Escherichia coli vitality and improves survival in an Escherichia coli-induced murine sepsis model.

Authors:  Wei-chang Shen; Xu Wang; Wei-ting Qin; Xue-feng Qiu; Bing-wei Sun
Journal:  Acta Pharmacol Sin       Date:  2014-11-17       Impact factor: 6.150

Review 2.  Toward Carbon Monoxide-Based Therapeutics: Critical Drug Delivery and Developability Issues.

Authors:  Xingyue Ji; Krishna Damera; Yueqin Zheng; Bingchen Yu; Leo E Otterbein; Binghe Wang
Journal:  J Pharm Sci       Date:  2016-01-06       Impact factor: 3.534

Review 3.  Application of metal coordination chemistry to explore and manipulate cell biology.

Authors:  Kathryn L Haas; Katherine J Franz
Journal:  Chem Rev       Date:  2009-10       Impact factor: 60.622

4.  Carbon monoxide liberated from CO-releasing molecule (CORM-2) attenuates ischemia/reperfusion (I/R)-induced inflammation in the small intestine.

Authors:  Kazuhiro Katada; Aurelia Bihari; Shinjiro Mizuguchi; Norimasa Yoshida; Toshikazu Yoshikawa; Douglas D Fraser; Richard F Potter; Gediminas Cepinskas
Journal:  Inflammation       Date:  2010-04       Impact factor: 4.092

5.  Nrf2 is essential for the anti-inflammatory effect of carbon monoxide in LPS-induced inflammation.

Authors:  SiYuan Qin; RongHui Du; ShaSha Yin; XinFeng Liu; GeLin Xu; Wangsen Cao
Journal:  Inflamm Res       Date:  2015-06-07       Impact factor: 4.575

6.  IL-10/HMOX1 signaling modulates cochlear inflammation via negative regulation of MCP-1/CCL2 expression in cochlear fibrocytes.

Authors:  Jeong-Im Woo; Sung-Hee Kil; Sejo Oh; Yoo-Jin Lee; Raekil Park; David J Lim; Sung K Moon
Journal:  J Immunol       Date:  2015-03-16       Impact factor: 5.422

7.  CO liberated from CORM-2 modulates the inflammatory response in the liver of thermally injured mice.

Authors:  Bing-Wei Sun; Yan Sun; Zhi-Wei Sun; Xi Chen
Journal:  World J Gastroenterol       Date:  2008-01-28       Impact factor: 5.742

8.  Carbon monoxide rescues heme oxygenase-1-deficient mice from arterial thrombosis in allogeneic aortic transplantation.

Authors:  Bo Chen; Lingling Guo; Chunlan Fan; Subhashini Bolisetty; Reny Joseph; Marcienne M Wright; Anupam Agarwal; James F George
Journal:  Am J Pathol       Date:  2009-06-04       Impact factor: 4.307

9.  Water-soluble carbon monoxide-releasing molecules: helping to elucidate the vascular activity of the 'silent killer'.

Authors:  Prabal Kumar Chatterjee
Journal:  Br J Pharmacol       Date:  2004-05-17       Impact factor: 8.739

10.  Vasoactive properties of CORM-3, a novel water-soluble carbon monoxide-releasing molecule.

Authors:  Roberta Foresti; Jehad Hammad; James E Clark; Tony R Johnson; Brian E Mann; Andreas Friebe; Colin J Green; Roberto Motterlini
Journal:  Br J Pharmacol       Date:  2004-05-17       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.